Загрузка...
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
Imatinib, which is an inhibitor of the BCR-ABL tyrosine kinase, has been a remarkable success for the treatment of Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemias (CMLs). However, a significant proportion of patients chronically treated with imatinib develop resistance because...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
National Academy of Sciences
2005
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC546016/ https://ncbi.nlm.nih.gov/pubmed/15677719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0408283102 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|